Dieila Giomo de Lima

Dr. Dieila Giomo de Lima

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022
Verified
Journal Article
Closed access
Dieila Giomo de LimaDieila Giomo de Lima
Dieila Giomo de Lima
GAGuilherme Castro Lima Silva Do Amaral
Guilherme Castro Lima Silva Do Amaral
APAline Cristiane Planello
Aline Cristiane Planello
GBGabriell Bonifacio Borgato
Gabriell Bonifacio Borgato
GGGustavo Narvaes Guimarães
Gustavo Narvaes Guimarães
Ana Paula de SouzaAna Paula de Souza
Ana Paula de Souza

29 May 2025 in Cancer Prevention Research
Verified
Journal Article
Open access
LPLaura Palmieri
Laura Palmieri
FZFernando T. Zamuner
Fernando T. Zamuner
Dieila Giomo de LimaDieila Giomo de Lima
Dieila Giomo de Lima
KGKeerthana Gosala
Keerthana Gosala
EWEli Winkler
Eli Winkler
RGRafael Guerrero-Preston
Rafael Guerrero-Preston
Cervical cancer is one of the most common cancers in women. Despite progress in prevention and success in early detection through cytologic screening and human papillomavirus (HPV) detection, there remains a challenge in triaging women appropriately to colposcopy and biopsy. We sought to validate the CervicalMethDx test, a precision DNA methylation classifier for cervical cancer detection, as a reflex test in women with HPV-positive samples. A blinded retrospective study was performed on well-characterized samples in PreservCyt media from a large referral clinical laboratory in the United States. DNA methylation was assessed in three gene promoters (ZNF516, FKBP6, and INTS1) and a control gene (β-actin) by quantitative real-time methylation-specific PCR (qMSP) analysis, using machine learning algorithms. We compared DNA methylation levels in HPV-positive patients presenting with lesions in the Pap test and cervical intraepithelial neoplasia grade 2 (CIN2) or CIN3 histologic diagnosis with DNA methylation levels in HPV-positive patients with lesions in the Pap test but no intraepithelial lesion or malignancy. The CervicalMethDx test correctly classified 95% of the CIN2 samples (n = 210), with 91% sensitivity, 100% specificity, and an area under the ROC curve (AUC) of 0.96, and 94% of CIN3 samples (n = 141), with 90% sensitivity, 100% specificity, and an AUC of 0.96. Moreover, the CervicalMethDx test correctly classified 94% of combined CIN2/CIN3 samples (n = 351), with 93% sensitivity, 97% specificity, and an AUC of 0.96. CervicalMethDx demonstrated strong discriminatory power for identifying CIN2/CIN3 risk and may complement current triage strategies for colposcopy referral. Prospective, population-based studies, including those in low-resource settings, are needed for further evaluation. Prevention Relevance: The CervicalMethDx test integrates DNA methylation analysis and machine learning to improve early detection of high-grade cervical lesions (high-grade squamous intraepithelial lesions), offering a noninvasive, cost-effective screening tool. Enhanced risk stratification and overtreatment reduction expand equitable access to precision prevention programs. Further validation will clarify CervicalMethDx’s alignment with global cervical cancer prevention strategies.

1 May 2019 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Closed access
GAGuilherme C.L.S. Do Amaral
Guilherme C.L.S. Do Amaral
APAline C. Planello
Aline C. Planello
GBGabriell Borgato
Gabriell Borgato
Dieila Giomo de LimaDieila Giomo de Lima
Dieila Giomo de Lima
GGGustavo N. Guimarães
Gustavo N. Guimarães
Ana Paula de SouzaAna Paula de Souza
Ana Paula de Souza

13 August 2025 in Cancer Biology & Therapy
Verified
Journal Article
Open access
LKLarissa Akemi Kido
Larissa Akemi Kido
MMMilena Rodrigues Marusco
Milena Rodrigues Marusco
ESEllen Aparecida da Silva
Ellen Aparecida da Silva
LCLaís Do Carmo
Laís Do Carmo
ABAna Beatriz Teodoro Borges
Ana Beatriz Teodoro Borges
PZPriscila Pini Zenatti
Priscila Pini Zenatti
Developing advanced preclinical models and targeted therapies is essential for reducing cancer-related deaths in children with solid tumors. Patient-derived xenografts (PDX) have the potential to replicate key elements of the original tumor, including morphology, genetic alterations, and microenvironment, making them valuable tools for studying tumor biology and drug response. We implanted 124 pediatric solid tumor samples, collected for 1 y, into NOD/SCID/IL2Rg (NSG) mice. Tumor fragments were placed subcutaneously, and the animals were monitored for up to 1 y. Histopathology, Short Tandem Repeat (STR) profiling, RT-PCR and/or RNA-sequencing were performed to confirm tumor identity and detect driver fusions. Fifty-five xenografts were successfully established (44.35% of implanted samples), representing 19 tumor types. Sarcomas, notably osteosarcoma, Ewing sarcoma, synovial sarcoma, and rhabdomyosarcoma, displayed first-generation engraftment rates above 55%. Central nervous system tumors had lower success, reflecting unique microenvironmental requirements. Histopathology and STR concordances were 85.45% and 81.1%, respectively, while 92.6% of sarcoma PDXs retained original fusion genes. Second-generation xenografts showed faster growth, suggesting adaptation to the murine host. Sporadic discrepancies, such as new fusions or lymphoproliferative expansions, indicated the need for ongoing molecular validation parallel to other techniques. A pediatric PDX biobank can effectively capture key tumor features while facilitating the study of therapeutic responses and tumor evolution. Our models confirm the feasibility of achieving stable histological and molecular profiles, offering a valuable resource for precision oncology research. Ultimately, these pediatric PDXs could accelerate the discovery of targeted therapy and significantly improve treatment outcomes.

7 January 2021 in Australian Endodontic Journal
Verified
Journal Article
Closed access
PDF file
LRLiliane Roskamp
Liliane Roskamp
PTPaula Cristina Trevilatto
Paula Cristina Trevilatto
Cleber Machado-SouzaCleber Machado-Souza
Cleber Machado-Souza
SISergio Aparecido Ignácio
Sergio Aparecido Ignácio
Dieila Giomo de LimaDieila Giomo de Lima
Dieila Giomo de Lima
VWVânia Portela Ditzel Westphalen
Vânia Portela Ditzel Westphalen

1 October 2025 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Open access
MEMayara Euzebio
Mayara Euzebio
FSFelipe Luz Torres Silva
Felipe Luz Torres Silva
IHIva L. Hoffmann
Iva L. Hoffmann
JRJuliana Ruas
Juliana Ruas
LKLarissa Akemi Kido
Larissa Akemi Kido
Mariana MaschiettoMariana Maschietto
Mariana Maschietto
Paediatric central nervous system (CNS) tumours are the second most common childhood malignancy and the leading cause of cancer‐related mortality in this age group. Histopathological diagnosis can be challenging, particularly for rare or ambiguous tumours, and may result in misclassification. To evaluate the utility of DNA methylation profiling in a middle‐income country, we performed the Infinium MethylationEPIC BeadChip (Illumina) on tumours from 182 paediatric patients treated at a reference centre for paediatric oncology in Campinas, state of São Paulo, Brazil. Data were analysed using the DKFZ/Heidelberg CNS tumour classifier (v12.8). After excluding control tissue, 163 samples (89.6%) were suitable for classification; 135 (74.2%) achieved a calibrated score ≥ 0.9 and were assigned to a methylation class family. Methylation profiling resulted in a tumour subtype for 88 cases (65.7%) and changed the diagnosis in 28 cases (20.9%), identifying several rare tumour subtypes that were identified solely through methylation analysis, confirming the value of this method in improving diagnostic accuracy. This study highlights the utility of DNA methylation profiling for paediatric CNS tumours in a resource‐limited setting and provides a cohort from an underrepresented middle‐income population to international molecular databases.